- Policy
- Announcement of drug price reform is delayed
- by Kim, Jung-Ju Jan 4, 2020 08:47pm
- The reform of the drug price system, which the government plans to announce last month, is delayed somewhat. The pharmaceutical industry is all on edge because of the reorganization of generic drug prices, improved risk-sharing contract (RSA), economic exemption system, and insurance policy supplementary agreement (sub-contract). ◆Generic
- Opinion
- [Reporter’s View] At least a guideline for ‘class effect’
- by Eo, Yun-Ho Jan 3, 2020 06:33am
- ‘Recognizing expected efficacy of drugs with same mechanism of action.’ It is definitely an unresolved conundrum. Experts have clashing opinions and each pharmaceutical company has different interests. In the end, what it comes down to is ‘case by case.’ Not that it needs an answer key, but obviously the prescribing doctor’s decis
- Policy
- Only 6 out of 9 reimbursed use of Spinraza approved
- by Lee, Hye-Kyung Jan 3, 2020 06:31am
- Only 66.6 percent of preliminary approval applications for reimbursement submitted last month was cleared for the use of spinal muscular atrophy (SMA) treatment Spinraza (nusinersen). Six out of nine applications were approved, and other three applications were rejected with conditional approval, disapproval and required supplementary data.
- Company
- Daewoong launches 'Nabota' Phase III clinical trial in China
- by An, Kyung-Jin Jan 2, 2020 11:26pm
- Nabota, a botulinum toxin preparation developed by Daewoong Pharm. Co., Ltd (CEO Seung-ho Jeon), has begun preparations for clinical trials in China. Daewoong Pharm. Co., Ltd announced on the 31st that it held a researcher meeting for Nabota's phase III clinical trials in China at the Pullman Skyway Hotel in Shanghai on the 28th. Daewoo
- Policy
- Rare cancer reoccurred in patients with Allergan’s implants
- by Lee, Tak-Sun Jan 2, 2020 11:21pm
- Another patient with rare cancer developed after breast augmentation with Allergan’s coarse surface implants. This is the second time since it was first reported in Korea on August 14th. The Minister of Food and Drug Safety, Eui-Kyung Lee and the Korean Society of Plastic and Reconstructive Surgeon(Chairman, Kwang Seog Kim) announced on t
- Policy
- Reimbursed Dupixent requires prior prescription record
- by Kim, Jung-Ju Jan 2, 2020 11:20pm
- The reimbursement criteria for patients taking now listed Sanofi Aventis Korea’s severe atopic dermatitis treatment Dupixent Pre-filled syringe 300 mg (dupilumab) were officially disclosed. Reimbursement on the treatment is granted for an adult patient age over 18 with chronic and severe atopic dermatitis symptoms continuing over three
- Policy
- ₩2.8 billion will be invested in AI drug development
- by Kim, Jung-Ju Jan 2, 2020 06:09am
- The government will greatly strengthen investment in innovation growth in the biohealth sector, which is called the future food industry, such as the pharmaceutical industry and increased the budget by 13% to &8361;527 billion, and doubled the budget by building big data, new drug development platform, and support for the development of th
- InterView
- “Key to healthcare innovation is pharmaceutical industry"
- by Kim, Jung-Ju Jan 2, 2020 06:08am
- Korea’s Ministry of Health and Welfare (MOHW) has stated two core goals of the current administration are ‘creating an inclusive welfare state’ and ‘supporting innovative growth of emerging industry.’ The key is definitely the pharmaceutical industry. During a question and answer session with correspondents, Park Min-soo, a direc
- Product
- Samsung completes Phase III of Lucentis Biosimilar
- by Lee, Seok-Jun Jan 2, 2020 06:08am
- Samsung Bioepis’ Lucentis Biosimilar (SB11)' phase III completed. Lucentis' global sales last year were about ￦4.2 trillion. Samsung Bioepis recently announced its last patient visit for the SB11 phase III trial was done. Phase III examined compared non-inferiority with the original Lucentis in a total of 705 patients with Wet Age
- Policy
- Lipiodol’s gap recurrence prevention law is pushed forward
- by Lee, Jeong-Hwan Jan 2, 2020 06:06am
- A bill, which the government is obliged to conduct regular surveys on the state of supply of essential medicines, to build a stable supply environment will be promoted. The legislative goal is to prevent the gap of essential medicines to prepare for major national disasters such as terrorism and radioactive pollution. Representative Myu
